IMUC
EOM PHARMACEUTICAL HLDNGS
stockOTC
immunocellular therapeutics, ltd. is a los angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. immunocellular has concluded a phase 2 trial of its lead product candidate, ict-107, a dendritic cell-based immunotherapy targeting multiple tumor-associated antigens on glioblastoma stem cells. immunocellular's pipeline also includes: ict-121, a dendritic cell immunotherapy targeting the cd133 antigen on stem cells in recurrent glioblastoma; ict-140, a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells; and the stem-to-t-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing t-cells.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.11 | 2026-09-29 | +39.18% | 94.487 |
| 1M | 0.15 | 2026-09-04 | +5.16% | 15.681 |
| 3M | 0.20 | 2026-07-06 | -20.55% | 18.371 |
| 6M | 0.17 | 2026-04-01 | -6.47% | 0.789 |
| 1Y | 0.08 | 2025-10-03 | +109.49% | 4.476 |
| 2Y | 0.12 | 2024-10-03 | +35.81% | — |
| 5Y | 0.56 | 2021-10-04 | -71.63% | 0.824 |
EOM PHARMACEUTICAL HLDNGS (OTC:IMUC) stock price today is $0.16, and today's volume is 200. IMUC is up 47.430% today. The 30 day average volume is 3,972. IMUC market cap is $18.00M with 113.27M shares outstanding.